PRPH on OTC

ProPhase Labs

American biotechnology company founded in 19891

In its 2026 annual report the company says: “We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. We offer whole genome sequencing and related services through our wholly-owned subsidiary, Nebula Genomics, Inc. and DNA Complete, Inc. Our wholly owned subsidiary, ProPhase BioPharma, Inc. is focused on the licensing, development and commercialization of novel drugs, dietary supplements, and compounds.”5 It is headquartered in New York, New York.1 Its shares trade on OTC under the symbol PRPH.1

Price unavailable

Last updated Oct 20, 2026.

Overview

1989Founded1

Compare with CHINA PHARMA HOLDINGS, INC., XBiotech Inc. or CervoMed Inc., or pick any stock.

  • TickerPRPH on OTC1
  • Industrybiotechnology industry, pharmaceutical industry1
  • HeadquartersNew York, New York1
  • Incorporated inDE3
  • Business address711 Stewart Ave, Suite 200, Garden City, New York, Ny 115303
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

31.9%Gross margin6
-415.4%Operating margin6
-339.3%Net margin6
-35.8%Revenue growth, 20256
-420.3%Return on equity6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue68¢$3.0M
  • Research and development2¢$107.0K
  • Other costs29¢$1.3M

Out of $4.3M in revenue.6 The company lost money this year.

Financial statements

Revenue78910116$4.3M in 2025−56% since 2019
0$50.0M$100.0M$150.0M2019: $9.9M$9.9M20192020: $14.5M$14.5M2020+47%2021: $79.0M$79.0M2021+445%2022: $122.6M$122.6M2022+55%2023: $35.0M$35.0M2023−71%2024: $6.8M$6.8M2024−81%2025: $4.3M$4.3M2025−36%
Gross profit78910116$1.4M in 2025−47% since 2019
-$20.0M0$20.0M$40.0M$60.0M$80.0M2019: $2.6M$2.6M20192020: $4.6M$4.6M2020+76%2021: $42.0M$42.0M2021+812%2022: $70.7M$70.7M2022+68%2023: $15.6M$15.6M2023−78%2024: -$150.0K-$150.0K20242025: $1.4M$1.4M2025
Operating income78910116-$18.0M in 2025+457% since 2019
-$40.0M-$20.0M0$20.0M$40.0M2019: -$3.2M-$3.2M20192020: -$2.1M-$2.1M2020−36%2021: $9.8M$9.8M20212022: $23.6M$23.6M2022+141%2023: -$21.2M-$21.2M20232024: -$38.6M-$38.6M2024+82%2025: -$18.0M-$18.0M2025−53%
Net income78910116-$14.7M in 2025+369% since 2019
-$60.0M-$40.0M-$20.0M0$20.0M2019: -$3.1M-$3.1M20192020: -$2.1M-$2.1M2020−32%2021: $6.3M$6.3M20212022: $18.5M$18.5M2022+194%2023: -$16.8M-$16.8M20232024: -$53.4M-$53.4M2024+218%2025: -$14.7M-$14.7M2025−72%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Revenues, net$4.3M$6.8M
Cost of revenues$3.0M$6.9M
Gross profit (loss)$1.4M-$150.0K
General and administration$19.3M$37.9M
Research and development$107.0K$594.0K
Total operating expenses$19.4M$38.5M
Loss from operations-$18.0M-$38.6M
Loss from investment in unconsolidated affiliates-$166.0K$0
Change in fair value of warrant liability-$225.0K$0
Change in fair value of derivative liability$437.0K$0
Interest expense-$6.9M-$3.4M
Debt extinguishment gain (loss)$838.0K-$333.0K
Loss on issuance of debt-$480.0K$0
Loss from disposal of fixed assets-$955.0K$0
Employee retention tax credit income$2.3M$0
Other expense-$174.0K-$18.0K
Loss from operations before income taxes-$23.4M-$42.3M
Income tax expense$0-$7.2M
Loss from continuing operations after income taxes-$23.4M-$49.5M
Loss from discontinued operations, net of tax-$102.0K-$3.8M
Gain from disposal of discontinued operations$8.7M$0
Income (loss) from discontinued operations$8.6M-$3.8M
Net loss-$14.7M-$53.4M
Unrealized income (loss) on marketable securities$0$102.0K
Total comprehensive loss-$14.7M-$53.3M
Loss from continuing operations, basic (in dollars per share)-$3-$25
Loss from continuing operations, diluted (in dollars per share)-$3-$25
Gain/(Loss) from discontinued operations, basic (in dollars per share)$1-$2
Gain/(Loss) from discontinued operations, diluted (in dollars per share)$1-$2
Net loss per share, basic (in dollars per share)-$1.74-$26.68
Net loss per share, diluted (in dollars per share)-$1.74-$26.68
Basic (in shares)8.5M shares2.0M shares
Diluted (in shares)8.5M shares2.0M shares

Compare ProPhase Labs with another company

Corporate structure

ProPhase Labs sits at the top of its group. 13 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ProPhase Labs

  • Ted William Karkus Filed SC 13D/A on ProPhase Labs, latest Mar 19, 2024 (8 filings since May 26, 2022)
  • ProPhase Labs New York, New York
    • DNA Complete, Inc. Subsidiary · Delaware, United States
    • Nebula Genomics Holdings, Inc. Subsidiary · Delaware, United States
    • Nebula Genomics, Inc. Subsidiary · Delaware, United States
    • ProPhase Billing Services, Inc. Subsidiary · Delaware, United States
    • ProPhase Biopharma, Inc. Subsidiary · Delaware, United States
    • ProPhase Diagnostics NY, Inc. Subsidiary · Delaware, United States
    • ProPhase Diagnostics UT, Inc. Subsidiary · Delaware, United States
    • ProPhase Diagnostics, Inc. Subsidiary · Delaware, United States
    • ProPhase Digital Media, Inc. Subsidiary · Delaware, United States
    • ProPhase Global Healthcare, Inc. Subsidiary · Delaware, United States
    • Quigley Pharma Inc. Subsidiary · Delaware, United States
    • TK Supplements, Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ProPhase Labs reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Finance-lease assets$2.0M6 Dec 31, 2025$4.2M6 Dec 31, 2024−53.4%
Operating-lease assets (leased space)$06 Dec 31, 2025$4.1M6 Dec 31, 2024−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$90.0K6 Dec 31, 2025$678.0K6 Dec 31, 2024−86.7%
Marketable securities, current$06 Dec 31, 2025$3.1M6 Dec 31, 2024−100.0%
Stakes in other companies (equity method)$43.5M6 Dec 31, 2025$06 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$4.0M6 Dec 31, 2025$5.2M6 Dec 31, 2024−24.1%
Intangible assets, net (excluding goodwill)$7.2M6 Dec 31, 2025$9.8M6 Dec 31, 2024−26.5%
Finite-lived intangibles, gross$17.8M6 Dec 31, 2025$19.1M6 Dec 31, 2024−6.8%
Accumulated amortization$10.6M6 Dec 31, 2025$9.4M6 Dec 31, 2024+13.6%
Finite-lived intangibles, net$7.2M6 Dec 31, 2025$9.8M6 Dec 31, 2024−26.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$70.0K6 Dec 31, 2025$1.1M6 Dec 31, 2024−93.9%
Raw materials$2.0K6 Dec 31, 2025$147.0K6 Dec 31, 2024−98.6%
Work in process$06 Dec 31, 2025$65.0K6 Dec 31, 2024−100.0%
Finished goods$68.0K6 Dec 31, 2025$375.0K6 Dec 31, 2024−81.9%

Properties, in its own words

Our principal executive offices are located in Uniondale, New York, where we lease office space pursuant to a month-to-month shared office arrangement. The space consists of a small executive office suite utilized for administrative purposes. We believe our current facilities are adequate for our present operations.

Item 2 of the 10-K filed Jun 1, 2026.5

Leadership

Who has led ProPhase Labs, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Guy J. Quigley2006–2007
  2. Ted William Karkus2010–now

Chair

  1. Guy J. Quigley2006–2007
  2. Ted William Karkus2010–now

President

  1. Guy J. Quigley2006–2007

Chief financial officer

  1. George J. Longo2006
  2. Gerard M. Gleeson2008
  3. Robert Cuddihy V. Jr.2011–2017
  4. Monica L. Brady2019–2020
  5. Robert A. Morse Jr.2023

Chief operating officer

  1. Robert Cuddihy V. Jr.2009–2014
  2. Jed Latkin2024
  3. Stuart Hollenshead2025–now
19901995200020052010201520202025
Board members and other officers (19)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorLOUIS GECKEL named Jul 7, 2025 to Aug 5, 202541

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • DNA Complete, Inc. Delaware4
  • Nebula Genomics Holdings, Inc. Delaware4
  • Nebula Genomics, Inc. Delaware4
  • ProPhase Billing Services, Inc. Delaware4
  • ProPhase Biopharma, Inc. Delaware4
  • ProPhase Diagnostics NY, Inc. Delaware4
  • ProPhase Diagnostics UT, Inc. Delaware4
  • ProPhase Diagnostics, Inc. Delaware4
  • ProPhase Digital Media, Inc. Delaware4
  • ProPhase Global Healthcare, Inc. Delaware4
  • Quigley Pharma Inc. Delaware4
  • TK Supplements, Inc. Delaware4

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. Sep 24, 2024DNA Complete became a subsidiary1
  2. Aug 2021Nebula Genomics became a subsidiary1

Former names

  • QUIGLEY CORPOct 25, 1996 to May 18, 20103

Timeline

  1. Aug 6, 20268-K Entered a material agreement; New debt or obligation42
  2. Feb 13, 20268-K Other events43
  3. Feb 13, 20268-K Other events44
  4. Jan 27, 20268-K Other events45
  5. Jan 23, 20268-K Entered a material agreement; Unregistered sale of shares46
  6. Jan 23, 20268-K Other events47
  7. Jan 9, 20268-K Executive or director change48
  8. Jan 9, 20268-K Other events49
  9. Jan 2, 20268-K Listing notice or transfer50
  10. Dec 19, 20258-K Other events51
  11. Dec 19, 20258-K Other events52
  12. Dec 18, 20258-K Bylaws or fiscal year changed; Other events53
  13. Dec 15, 2010New chief executive Ted William Karkus becomes CEO14
  14. Mar 22, 2006New chief executive Guy J. Quigley becomes CEO15
  15. Feb 3, 1995Went public Listed on NASDAQ1
  16. 1989Founded Founded1

Calendar

When it reported results

  1. Nov 19, 2025Reported quarterly or annual results54
  2. Aug 13, 2025Reported quarterly or annual results55
  3. May 20, 2025Reported quarterly or annual results56
  4. Mar 31, 2025Reported quarterly or annual results57
  5. Nov 13, 2024Reported quarterly or annual results58
  6. Aug 14, 2024Reported quarterly or annual results59
  7. May 9, 2024Reported quarterly or annual results60
  8. May 9, 2024Reported quarterly or annual results61

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

220 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 100 major events, 35 insider forms, 8 large holders, 2 private raises, 51 other. The latest 20:

  1. Aug 19, 202610-Q EDGAR
  2. Aug 14, 2026NT 10-Q EDGAR
  3. Aug 6, 20268-K EDGAR
  4. Jul 9, 202610-Q/A EDGAR
  5. Jul 7, 202610-Q/A EDGAR
  6. Jun 30, 202610-Q EDGAR
  7. Jun 1, 202610-K EDGAR
  8. May 15, 2026NT 10-Q EDGAR
  9. Mar 27, 2026NT 10-K EDGAR
  10. Feb 13, 20268-K EDGAR
  11. Feb 13, 20268-K EDGAR
  12. Jan 27, 20268-K EDGAR
  13. Jan 23, 20268-K EDGAR
  14. Jan 23, 20268-K EDGAR
  15. Jan 23, 202625-NSE EDGAR
  16. Jan 9, 20268-K EDGAR
  17. Jan 9, 20268-K EDGAR
  18. Jan 2, 20268-K EDGAR
  19. Dec 29, 2025424B5 EDGAR
  20. Dec 19, 20258-K EDGAR

The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 10, 2022Barr Jason MichaelDirectorBuy721$6.48$4.7KForm 4
Mar 10, 2022Barr Jason MichaelDirectorBuy750$6.48$4.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 22, 2025Raised $3 million in a private offering of debt Form D: $6 million offered in all Form D
  2. Jun 22, 2025Raised $1 million in a private offering of debt Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
CoreCap Advisors, LLC10$10.0%No change
Farther Finance Advisors, LLC10$10.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How ProPhase Labs is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARProPhase Labs, Inc.2
  • CIK0000868278
  • Employer ID (EIN)23-25771385
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address711 Stewart Ave, Suite 200, Garden City, New York, NY 115302
  • Phone(215) 345-09192
  • Shares outstanding15,592,556 as of Aug 17, 202613
  • Public float$15.2M as of Jun 30, 20255
  • AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceAug 13, 19962
  • Filings922 in all: 8-K (282), 4 (190), 10-Q (86), SC 13D/A (35), DEF 14A (34), 10-K (28), CORRESP (21), UPLOAD (19)2
    All 53 form types

    S-8 (18), 3 (15), 8-K/A (14), DEFA14A (14), ARS (13), DFAN14A (13), 424B5 (11), EFFECT (10), 4/A (9), S-3 (9), NT 10-Q (8), SC 13D (8), PRE 14A (7), 10-Q/A (6), SC 13G/A (6), 10-K/A (5), 424B3 (5), 10QSB (4), D (4), NT 10-K (4), POS AM (4), SC 13G (4), SC TO-I/A (4), 10KSB/A (3), 10KSB (2), 8-A12G (2), 8-A12G/A (2), FWP (2), PRER14A (2), PRRN14A (2), SB-2/A (2), SC TO-I (2), 10QSB/A (1), 15-12G (1), 25-NSE (1), 3/A (1), CT ORDER (1), DEFC14A (1), PREC14A (1), PREN14A (1), S-1 (1), S-3/A (1), S-3MEF (1), S-8 POS (1), SB-2 (1)

  • Latest filingsAnnual report (10-K) Jun 1, 2026
    Quarterly report (10-Q) Aug 19, 2026
    Proxy statement (DEF 14A) Oct 31, 2025
    Latest 8-K (8-K) Aug 6, 2026

Risk factors and legal proceedings

Legal proceedings

A qui tam complaint was filed under seal in the United States District Court alleging violations of the federal False Claims Act relating to certain laboratory testing activities of the Company’s diagnostic subsidiaries. Under the False Claims Act, the United States Department of Justice and relevant state authorities are afforded an opportunity to investigate the allegations and determine whether to intervene and take over prosecution of the action.

After reviewing the allegations and conducting their investigation, the United States Department of Justice and the relevant state authorities declined to intervene in the action. The matter was thereafter unsealed and the case remains pending. The named defendant diagnostic subsidiaries are the same entities that, on September 22, 2025, filed voluntary petitions under Chapter 11 of the Bankruptcy Code (see Note 18).

The Company believes the allegations are without merit and intends to defend the matter vigorously. The Company is not aware of any ongoing government investigation related to the allegations described above.The Company and the Debtors believe the allegations are without merit and intend to defend the matter vigorously. The Company is not aware of any ongoing government investigation relating to the allegations described above.

The Company is a party to a pending arbitration proceeding commenced by Turnpoint Capital, LLC ("Turnpoint") relating to a senior secured convertible note issued in July 2025. Turnpoint alleges certain events of default under the note and seeks monetary damages and other relief. The Company disputes the allegations, believes it has substantial defenses and affirmative claims relating to the matter, and intends to vigorously defend and prosecute the proceeding. The arbitration is in its early stages, and the Company cannot currently estimate the outcome, timing, or amount of any potential loss or recovery associated with the matter.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
    SEC EDGAROther events
  44. 44
    SEC EDGAROther events
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62